Schwab Charles Investment Management Inc. raised its holdings in Flexion Therapeutics Inc (NASDAQ:FLXN) by 53.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 165,222 shares of the specialty pharmaceutical company’s stock after acquiring an additional 57,672 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.44% of Flexion Therapeutics worth $4,138,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in FLXN. The Manufacturers Life Insurance Company lifted its holdings in Flexion Therapeutics by 3.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock valued at $441,000 after acquiring an additional 811 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in Flexion Therapeutics by 12.3% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 71,320 shares of the specialty pharmaceutical company’s stock valued at $1,725,000 after acquiring an additional 7,800 shares during the period. State Board of Administration of Florida Retirement System acquired a new stake in Flexion Therapeutics in the third quarter valued at $235,000. Russell Investments Group Ltd. lifted its holdings in Flexion Therapeutics by 2,458.8% in the third quarter. Russell Investments Group Ltd. now owns 127,430 shares of the specialty pharmaceutical company’s stock valued at $3,081,000 after acquiring an additional 122,450 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Flexion Therapeutics in the third quarter valued at $135,000. 94.71% of the stock is owned by institutional investors.
A number of equities research analysts have commented on FLXN shares. Berenberg Bank started coverage on Flexion Therapeutics in a report on Thursday, February 1st. They issued a “buy” rating and a $42.00 target price for the company. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 5th. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (down previously from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. Finally, BidaskClub raised Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $99.00.
Flexion Therapeutics Inc (NASDAQ:FLXN) opened at $23.53 on Friday. The company has a current ratio of 13.02, a quick ratio of 12.96 and a debt-to-equity ratio of 0.58. Flexion Therapeutics Inc has a one year low of $16.51 and a one year high of $32.25.
Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.27). The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $1.29 million. equities research analysts predict that Flexion Therapeutics Inc will post -4.89 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/03/18/flexion-therapeutics-inc-flxn-holdings-raised-by-schwab-charles-investment-management-inc.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.